Ocugen said it will push ahead with its late-stage gene therapy pipeline, highlighting a modifier gene therapy platform and three Phase 3 assets at the Stifel 2

Ocugen said it will push ahead with its late-stage gene therapy pipeline, highlighting a modifier gene therapy platform and three Phase 3 assets at the Stifel 2026 Healthcare Conference. It recently added a MENA licensing deal for OCU400 worth up to $259 million.